Fluorescent imaging agent goes to market
Fluorescent imaging agent goes to marketVPDiagnostics mints MR plaque analysis softwareZiosoft unveils subscription program
Fluorescent imaging agent goes to market
VisEn Medical, a specialist in fluorescence in vivo imaging, launched a new in vivo imaging agent for preclinical research. Following the launch of IntegriSense 680, the new agent, IntegriSense 750, is tuned to the assessment of integrin αvβ3, a biomarker closely associated with disease-related vascularity and angiogenesis. The agent was developed out of the Merck-VisEn Biomarker Imaging research collaboration to enable in vivo imaging of the biomarker's expression in order to measure and monitor aspects of disease progression and therapeutic response of disease states including oncology, cardiovascular disease, and bone disease.
VPDiagnostics mints MR plaque analysis software
Postprocessing software firm VPDiagnostics has developed a way to document carotid artery atherosclerosis MR angiograms. The tool, MRI-PlaqueView, is set to begin a multicenter clinical trial sponsored by the NIH. Cleared in December 2008, the software provides semiautomated tools, a streamlined workflow, and an optimized user interface.
Ziosoft unveils subscription program
The imaging community need not dip into its capital equipment budget for thin-client postprocessing from Ziosoft. The Japanese company has launched a monthly subscription program that allows customers to gain access to its 3D advanced visualization system, which reconstructs large image data sets acquired from CT and MR systems.
Strategies to Reduce Disparities in Interventional Radiology Care
March 19th 2025In order to help address the geographic, racial, and socioeconomic barriers that limit patient access to interventional radiology (IR) care, these authors recommend a variety of measures ranging from increased patient and physician awareness of IR to mobile IR clinics and improved understanding of social determinants of health.
The Reading Room Podcast: Current Perspectives on the Updated Appropriate Use Criteria for Brain PET
March 18th 2025In a new podcast, Satoshi Minoshima, M.D., Ph.D., and James Williams, Ph.D., share their insights on the recently updated appropriate use criteria for amyloid PET and tau PET in patients with mild cognitive impairment.
Study: Monitoring of Prostate MRI Exams Could Lead to 75 Percent Reduction of Gadolinium Contrast
March 17th 2025While DCE MRI was deemed helpful in over 67 percent of cases in which it was used, researchers found that monitored prostate MRI exams, which facilitated a 75 percent reduction of DCE MRI sequences, had comparable sensitivity for prostate cancer as non-monitored exams.
